1. introduction - welcome to...
TRANSCRIPT
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
1
1. Introduction
M/s. Sri Krishna Pharmaceuticals Limited, Unit-III (Formerly Sri Krishna
Drugs Limited) was established in the year 1988. It is located at Sy. No.
57, Golkonda kalan, Raikunta (V), shamshabad (M), Rangareddy (D),
Telangana state .
The unit obtained NOC (CFE) of A.P. Pollution control Board in the year
1988 and started operations.
The Ministry of Environment and Forests accorded Environmental
Clearance to the industry vide Environmental Clearance File No: J-
11011/147/2005-IA.II(I) Dt: August 11,2005 to manufacture folic acid
with a capacity of 96.0 TPA. Copy of Environmental clearance is enclosed
as Annexure I. The unit obtained CFE for Change of Product mix vide
order No. APPCB/HYD/KTN/311/CFE/HO/2009 dated 25.06.2010 and also
vide order No. 311/TSPCB/CFE/RO-RR-I/HO/2014-1262 dated
20.03.2015. Copy of latest CFE is enclosed as Annexure II.
Subsequently obtained CFO of the Board vide letter No.
APPCB/10017/ZO-HYD/ HO/CFO/2014-112 dated 04.04.2014 with a total
capacity of 8.0 TPM. Current CFO Copy is enclosed as Annexure III
In order to meet the market demand it is now proposed to expand the
production capacity from 96.0 TPA to 589.4 TPA.
Applied for Certified Copy of Compliance Report from MoEF & CC,
Government of India, Chennai Regional Office is enclosed at Annexure- IV
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
2
2. Introduction of the Project
The salient features of the project are described in the table given below
TABLE 1.0
Salient Features of the Project
Location Sy. No. 57, Golkonda kalan, Raikunta (V),
shamshabad (M), Rangareddy (D), Telangana
Longitude and Latitude 17o11’58.6’’ N & 17o12’04.6’’ N Latitude 78o25’08.8’’ E & 78o25’18.3’’ E Longitude
Year of Establishment 1988
Product Category 5(F) Bulk Drugs & Intermediates
Project Category as per EIA notification
“A” ( Not in notified Industrial Estate)
Proposed Activity Capacity expansion from 96.0 TPA to 589.4 TPA
Total investment on the plant Current - Rs. 31.85 Crores & Proposed – Rs.40.0 Crores
Total Investment on Environmental Infrastructure
Rs. 5.0 Crores (Current) Rs. 10.00 Crores ( Proposed)
Total area of the plant 12.0 Acres
Total area of green belt 5.0 Acres
Water requirement Total water requirement after expansion 802.30 KLD
Fresh water requirement 552.3 KLD Recycled water 250.0 KLD
Source of water Borewell Nearest habitation and distance from the site
Bahadurguda -1.71 Km
Nearest surface water bodies Rainfed water tank at a distance of 0.78
Km from site
Nearest reserve forest Nearest Reserve forest is at a distance of
1.4 km.
Environmentally sensitive areas
within 10 km radius None
Any national parks, wild life
sanctuaries within 10 km radius None
Nearest air port and distance Shamshabad, RGI-3 Km
Nearest railway station and distance
Umdanagar-7.43 Km
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
3
i) Introduction of the company and proponent
Sri Krishna Pharmaceuticals Limited, unit-III (Formerly Sri Krishna Drugs
Limited) was incorporated as a public limited company under the
Companies Act, 1956 at Hyderabad in the state of Andhra Pradesh, India
during the year 1988. The company is engaged in the manufacturing of
Active Pharmaceutical Ingredients (APIs) and API Intermediates for
catering to the domestic as well as international market.
The company recognized the vital role of R & D for becoming successful in
the generic market.
About Proponent
The management at Sri Krishna Pharmaceuticals Limited, Unit-III
(Formerly Sri Krishna Drugs Limited) consists of highly qualified and richly
experienced persons who have given the company the edge in terms of
quality, consistency, timely delivery and ability.
The company is headed by Mr. V. V Krishna Reddy, Managing Director,
having vast experience in various businesses.
About the Unit
Sri Krishna Pharmaceuticals Limited established this manufacturing unit in
the year 1988 and obtained Environmental Clearance from Ministry of
Environment with a capacity to manufacture Bulk Drugs with a capacity of
96.0 TPA.
Quality Management: Strict quality control measures, Good
Manufacturing Practices (GMP) are integrated throughout the
manufacturing process to ensure strict adherence to the quality
parameters for both in-process and finished products.
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
4
3. Project Description
3.1 Production Capacity
Currently the unit is permitted to manufacture 11 drugs out of which 4
are regular products and 7 are campaign products (any 3 products can be
manufactured at a given point of time) with a total capacity of 8.0 TPM as
detailed below
TABLE 2.0
LIST OF EXISTING PRODUCTS
S.No Name of the Products Quantity in TPM
Regular Products
1 Folic acid pharma 4.0
2 Metadoxine 0.50
3 Fenoverine 0.30
4 Tiemonium methyl sulphate 1.20
Campaign Products( Group B) an three products at a time
5 Doxylamine succinate 0.250
6 Enalapril Maleate 0.750
7 Iso Metheptene Mucate 0.5
8 Phenylephrine Hydrochloride 0.750
9 Meclazine Hydrochloride 0.50
10 Sodium Phenyl Butyrate 0.350
11 Butrorphanol Tartrate 0.02
Total ( Worst combination) 8.0
3.1.1 Proposed expansion:
It is now proposed to expand the production capacity of the existing 1
product and to manufacture all the existing products. Below Table
provides list of products and proposed capacities.
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
5
TABLE 3.0
PROPOSED PRODUCTS & CAPACITY
S.No Name of the Products Quantity in TPM
1 Folic acid pharma 44.0
2 Metadoxine 0.50
3 Fenoverine 0.30
4 Tiemonium methyl sulphate 1.20
5 Doxylamine succinate 0.250
6 Enalapril Maleate 0.750
7 Iso Metheptene Mucate 0.5
8 Phenylephrine Hydrochloride 0.75
9 Meclazine Hydrochloride 0.50
10 Sodium Phenyl Butyrate 0.350
11 Butrorphanol Tartrate 0.02
Total 49.12
3.2 Manufacturing Process
Brief process description and process flow charts are given at Annexure
VI
3.3 Raw Materials
List of raw material product wise is given at Annexure V
3.4 Water Requirement
The water requirement will be met Ground water. The requirement for
water in this unit is for process and domestic purposes. The water balance
for daily consumption is presented below.
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
6
TABLE 4.0
Water Balance– Current & Proposed
S.
No Stream
Water requirement in KLD
Waste Water discharge in KLD
Proposed Method of
Treatment and Disposal
Current
After
Expansion Current
After
Expansion
1 Process
52.5
346.8
55.387
369.9
Stripper, MEE and ATFD
(Condensate to RO)
2 Washings
3.0 3.0
Stripper, MEE
and ATFD (Condensate to
RO)
3 Scrubbers 2.0 4.00 2.0 4.0
Stripper, MEE
and ATFD
(Condensate to RO)
4 Boiler 17.5 117.5 2.5 12.5
ETP followed by RO ( RO Reject
to MEE)
5 DM/Softener -- 3.0 -- 3.0
ETP followed by RO ( RO Reject
to MEE)
6 Cooling &
Regeneration 40.0 244.0 10.0 34.0
ETP followed by
RO ( Ro Reject to MEE)
7 Domestic 18.0 54.0 8.0 33.0
ETP followed by RO ( Ro Reject
to MEE)
8 Gardening 30.0 30.0 -- --
Total 160.0 802.3 77.88 459.4
3.5 Wastes generation and control systems
3.5.1 Liquid Effluents
As detailed in Table 4.0 waste water generation after expansion would be
459.4 KLD. It is proposed to segregate effluents into high COD and High
TDS stream and Low COD and Low TDS streams.
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
7
High TDS and High COD stream would be treated in stripper followed by
MEE and ATFD. The resultant sludge would be disposed to TSDF,
Hyderabad. The Low TDS stream would be treated along with MEE/ATFD
condensates in biological ETP followed by RO. The RO rejects would be fed
back to MEE. The Permeate from RO would be used for cooling tower
make up. Thus the treatment system proposed is based on “Zero Liquid
Discharge” (ZLD) Concept
The schematic diagrams of ETP proposed are given in Figure 1.1 and
Figure 1.2 below
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
8
Fig 1.1 Schematic Treatment Scheme of High TDS Effluents
Effluent from Process and Aq. Distillate to
Cement Plant/TSDF Recovery Washings, Scrubber
RO Reject To TSDF Condensate to Biological Treatment Condensate to Biological Treatment
Sludge to TSDF
Equalization
Tank
MEE
ATFD
Stripper
Neutralization
Tank
Settling
Tank
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
9
Fig 1.2 Low TDS Effluent Treatment System
Domestic effluent
Effluents from utilities & MEE condensate
Sludge to TSDF
Permeate for re-use
Rejects to MEE
Screen
Chamber
Sludge Holding Tank
Aeration
Tank2
Equalization
Tank
Neutralization
Tank
Clarifier
2
Holding
Tank
Filter Press Sludge Cake
Aeration
Tank1 Clarifier
1
Sand
filter
Carbon
Filter
Ultra
filtration RO
Screen
Chamber
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
10
3.5.2 Solid wastes management
Hazardous and non - hazardous wastes generated from the proposed
expansion project are detailed below. Mode of disposal are also identified
and listed. Adequate storage of hazardous waste is ensured at the site
TABLE 5.0
Solid Wastes and Disposal
S.N
o Description
Quantity
Remarks Current
TPM
After
Expansion TPM
1
MEE salts/ Gypsum/
Calcium Chloride equivalent salts
93.332
593.33*
Sent to TSDF, Dundigal
2 Inorganic salts -- 13.15 Sent to TSDF, Dundigal
3
Distillation bottom
Residue/In soluble organic
residue
3.887 5.46
Authorized cement plants for co-
processing/ TSDF, Dundigal
4 Spent carbon 0.157 0.21
5 ETP sludge -- 9.0 Sent to TSDF, Dundigal
6 Iron sludge 4.758 52.28
Authorized cement Industries
7 Spent Nickel 0.08 0.80
For re-processing
Total 102.214 674.23
8 Boiler Ash -- 600.0
Sold to brick manufacturers
9 Waste oil 70.0 LPM 100.00 Authorized recyclers/ re-
processors
10
Detoxified
Container and container liners
50 No’s/Month
100.00
After complete detoxification it
shall be disposed to the outside agencies
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
11
Of hazardous waste chemicals
11 Used lead acid batteries
10 Nos/Year
10.00 Authorized recyclers on buy back basis
12 Spent solvents 10 KL/
month 20.00kl/month
To authorized recyclers/cement industries for co-Processing
*Includes salts from MEE and Neutralization salts.
TSDF facility is about 70 KM from the site in Rangareddy District which is
created for catering the industries in this area. Transport of Hazardous
wastes to TSDF is done by the Ramky. In case other hazardous wastes,
authorized recyclers will transport the wastes
4. Site Analysis
4.1 Plant Location
M/S Sri Krishna Pharmaceuticals Limited, unit-III Sy. No. 57, Golkonda
kalan, Raikunta (V), shamshabad (M), Rangareddy (D), Telangana state.
The site is situated at 17o11’58.6” N and 17o12’04.6” N Latitude and
78o25’08.8” E and 78o25’18.3” E Longitude. The land area of the plant is
11.3 acres. The nearest habitation from the site is bahadurguda (V) at a
distance of 1.71 km. The nearest railway station located at Umdanagarat
7.43 KM from the Plant. There are no ecologically sensitive areas like
national parks, sanctuaries within 10 km radius of the site.
Following are the surroundings of the site
North – Private lands
South –Approach road followed by industry’s own land with guest
house
East – Private lands
West - Outer ring road
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
12
Following 9 reserve Forests are there within 10 KM radius of the site
Table 6.0
Reserve Forests in the study area
S.No Reserve Forest Direction from the
site
Distance from the
site (KM)
1 RF E 1.4
2 RF S 2.0
3 Maisaram SE 5.5
4 Lemur SE 5.8
5 Kongarkala SE 9.6
6 Jallapalli NE 9.6
7 Domnair NW 9.7
8 RF W 5.0
9 RF NE 3.7
Topo graphic features of the site and 10 KM study area and base map are
given at Fig 1.3 & 1.4.
Plant & Green Belt Photographs are given at Fig. 1.5
Site lay out map is given at Fig 1.6
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
13
Fig 1.3
Topo Sheet of the 10 KM study area
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
14
Fig 1.4
Base map of the study area
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
15
Fig 1.5
Plant & Green Belt Photographs
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
16
Fig 1.6
Site Lay Out Plan
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
17
5.0 Planning in Brief
The project is envisaged to be completed by December 2016, and the
production shall be initiated thereon. Consultants are identified for
preparing the detailed project report.
6. Resource requirements 6.1 Power Requirement and Supply/Source
The total power requirement is 6000 KVA. It shall be sourced from
TSCPDCL and D.G sets as alternative to Power failure.
6.2 Production facilities, Utilities and effluent handling facilities
Apart from the existing facilities it is proposed to add additional
production facilities, utilities and effluents treatment infrastructure with
an additional investment of Rs.40.0 Crores. The details are outlined in the
below table
TABLE 7.0 Production facilities/Utilities/ETP – Existing & Proposed
S.NO Details
Capacity/
No Current
Additions
After
expansion
Production facilities
1 Production Blocks No’s 9 5 13
2 Clean Rooms No’s 30 5 35
Utilities
3 Boilers (Coal Fired) TPH 6 15 21
4 DG sets KVA 1 X500, 1 X 380
1000 1880
5 Cooling Towers TR 670 1500 2170
6 Softener/DM plant M3/hour 4000 4000 8000
Effluent handling & treatment facilities
7 collection tanks-Storage
KL 4 4 8
8 Neutralisation tanks KL 1 1 2
9 Stripper, MEE, ATFD KLD 150 400 550
12 RO & Biological
treatment
KLD 150 400 550
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
18
6.3 Land Requirement
The unit currently has 12.0 acres of land and out of which 5.0 acres of
green belt is developed. The land requirement for proposed expansion
activities will be 2.0 Acres which can be met from existing open area.
Below table provides the land statement. Detailed site lay out plan
outlining current and proposed expansion activities is given at Figure 1.6
Table 8.0 Land Statement
S.No Purpose Units Extent
1 Built up area Acres 2.0
2 Green belt Acres 5.0
3 Open area Acres 5.0
Total Acres 12.0
4 Area required for Proposed
expansion
Acres 2.0
7.0 Air Pollution
The Sources of air emissions from the plant are 6 TPH coal fired Boiler
and proposed 15.00 TPH coal fired boiler and additional DG sets
The process emissions from the second phase containing SO2, CH4, NH3 &
HCl are scrubbed with caustic and scrubbed waste send to MEE. Below
Table gives current proposed emission sources from the plant
Table 9.0
Emission Source – Current & Proposed
S.No
Parameter Capacity Fuel Anticipated emissions
Control system
Existing
1 Process --- -- HCl, SO2, NH3, Cl2
Scrubber
2 Boiler Stack 6 TPH Coal SPM, SO2,
NOx
Stack Ht 30
meters, bag filter & cyclone
dust collector
3 DG sets 1x 500 KVA Diesel SPM,SO2 Stack Height
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
19
and 1 X 380
KVA
&NOx 4.5 & 3.9 Mts,
Acoustic enclosures
Proposed (additions)
1 Boiler 15 TPH Coal SPM,SO2
&NOx
Bag filter &
Stack Height 30 meters
2 DG set 1000 KVA Diesel SPM, SO2, NOx
Stack height of 6.3 meters &
acoustic
enclosure
8.0 Bulk Chemical Storages:
Following bulk chemical storage facilities are proposed for expansion
activity
Table No 10.0
Storage facilities of bulk chemicals
Sr
No
Capacity
(KL)
Name of the
solvent/Chemical MOC
Existing
1 15 Methanol MS Tank
2 30 Acetone MS Tank
3 15 Tolune MS Tank
4 15 IPA MS Tank
5 6.0 Chloroform Drums
Other Major chemicals
6 30 tons chlorine MS
cylinder
7 10 HCl HDPE
8 40 H2SO4 MS
Proposed
9 10.00 Toluene MS Tank
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Unit-III
20
9. Project Financial
The estimated cost of the expansion project is approximately 40.0 Crores.
Out of this Rs. 10.00 Crores will be for effluents treatment facilities and
rest for other process equipment and safety equipment
Project cost
Rs. In
Crores
Plant& machinery 15.00
Civil & Structural 5.00
Total 20.00
Pipe lines & insulation
20% on plant &
machinery 4.00
Electricals & instrumentation 10% on plant & machinery 2.00
Erection & commissioning & painting
8% on plant &
machinery and structures 1.60
Safety & Environment 10.00
Furniture, fixtures, computers, lighting etc 0.50
Total 38.10
Contingencies & pre-operative
expenses
1.90
Project cost say 40.00 Crores